‘A watershed moment’: A pancreatic cancer drug is set to transform treatment
NBC News • • business
Key Points:
- Daraxonrasib, an experimental drug targeting the RAS protein mutation found in over 90% of pancreatic cancers, has shown to double survival times in patients with advanced pancreatic cancer when combined with chemotherapy.
- The FDA has fast-tracked daraxonrasib for approval and recently allowed expanded access for patients outside clinical trials, reflecting its potential to change pancreatic cancer treatment.
- Phase 1/2 trial results published in the New England Journal of Medicine showed progression-free survival of 8.1 months and overall survival of 15.6 months in advanced cases, significantly exceeding typical outcomes.
- Side effects include a severe rash, mouth sores, and gastrointestinal symptoms, but the drug is generally better tolerated than chemotherapy and taken orally, improving patient quality of life.
- Oncologists widely regard daraxonrasib as a major breakthrough in pancreatic cancer care, with ongoing research exploring its use as a first-line therapy and potential application in other RAS-mutated cancers like colorectal and lung cancer.
